Antimicrobial activity of non-steroidal anti-inflammatory drugs with respect to immunological response: Diclofenac sodium as a case study

African Journal of Biotechnology

Volumn 8, Issue 25, 2009, Pages 7332-7339

  Umaru, Titilayo ^a   Nwamba, Charles O ^b   Kolo, Ibrahim ^a   Nwodo, Uchechukwu U ^b  

^a NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Nigeria)

^b UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Biofilms; Diclofenac; Immunologic response; Inflammation; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; AUTACOID; CELECOXIB; CYTOKINE; DEXAMETHASONE; DICLOFENAC; ETODOLAC; FATTY ACID; IBUPROFEN; INDOMETACIN; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; THROMBOXANE;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BIOFILM; BIOSYNTHESIS; CANDIDA ALBICANS; CASE STUDY; CELL FUNCTION; CELL VIABILITY; CONCENTRATION RESPONSE; CULTURE MEDIUM; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; ESCHERICHIA COLI; FEVER; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY INFECTION; NECROTIZING FASCIITIS; NONHUMAN; PAIN; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; TISSUE INJURY;

BACTERIA (MICROORGANISMS);

EID: 74849103682     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Alem MAS, Douglas LJ (2004). Effects of aspirin and other nonsteroidal anti- inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob. Agents chemother. 48: 41-47.
2. Anderson AL, Hunt E, Davis BJ (1991). The influence of anti-inflammatory therapy on bacterial clearance following intramammary Escherichia coli Challenge in goats. Vet. Res. Commun. 15: 147-161.
3. Annaduri S, Basu S, Ray S, Dastidar SG, Chakrabarty AN (1998). Antimicrobial activity of the anti-inflammatory agent, diclofenac sodium. Indian J. Exp. Biol. 36: 86-90.
4. Aries JR, Kohler T, Nikaido H, Plesiat P (1999). Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycocides. Antimicrob. Agents. Chemother. 43: 2624-2628.
5. th ed. Appleton and Lange, USA, pp. 858-878.
6. Barnham M, Anderson AW (1997). Non-steroidal anti-inflammatory drugs: a pre-disposing fact for streptococcal bacteremia? Adv. Exp. Med. Biol. 418: 145-147.
7. Brooun A, Liu S, Lewis K (2000). A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 44: 640-646.
8. Chakrabarty AN, Acharya DP, Niyogi DK, Dastidar SG (1989). Drug inter-action of some non-conventional antimicrobial chemotherapeutic agents with special reference to promethazine. Indian J. Med. Res. 89: 233-237.
9. Chattopadhyay D, Dastidar SG, Chakrabarty AN (1988). Antimicrobial property of methdilazine and its synergism with antibiotics and some chemotherapeutic agents. Arzneim-Forsh/Drug Res. (FRG). 38: 869-872.
10. Costerton JW, Stewart PS, Greenberg EP (1999). Bacterial biofilms: a common cause of persistent infections. Science, 284: 1318-1322.
11. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM (1995). Microbial biofilms. Annu. Rev. Microbiol. 49: 711-745.
12. Coulie PG, Cayphas S, Vink A, Uyttenhove C, Van Snick J (1987). Interleukin- HP1-related hybridoma and plasmacytoma growth factors induced by lipopolysaccharide in vivo. Eur. J. Immunol. 17: 1217-1220.
13. Cox GM, Perfect JR (1993). Fungal infections. Curr. Opin. Infect. Dis. 6:422-426.
14. Dash SK, Dastidar SG, Chakrabarty AN (1977). Antimicrobial activity of promazine hydrochloride. Indian J. Exp. Biol. 15: 324-326.
15. Dastidar SG, Sarkor A, Kumar KA, Dutta NK, Chakraborty P (2003). Evaluation of in vitro and in vivo antibacterial activity of dobutamine hydrochloride. Indian J. Med. Microbiol. 21: 172-178.
16. Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN (2000). The antibacterial action of diclofenac shown by inhibition of DNA synthesis. Int. J. Antimicrob. Agents, 14: 249-251.
17. Dastidar SG, Saha PK, Sanyamat B, Chakrabarty AN (1976). Antibacterial activities of ambodryl and benadryl. J. Appl. Bact. 41: 209-214.
18. Dastidar SG, Mondal U, Niyogi S, Chakrabarty AN (1986). Antibacterial property of methyl-DOPA and development of cross-resistance in m-DOPA mutants. Indian J. Med. Res. 84: 142-147.
19. De Man P, van Kooten C, Aarden L, Engberg I, Linder H, Svanborg EC (1989). Interleukin -6 induced at mucosal surfaces by gram-negative bacterial infection. Infect. Immun. 57: 3383-3388.
20. De Man P, Jodal U, Lincoln K, Svanborg EC (1988). Bacterial attachment and inflammation in the urinary tract. J. Infect. Dis. 158: 29-35.
21. Dinarello CA, Cannon JG, Wolf SM (1988). New concepts on the pathogenesis of fever. Rev. Infect. Dis.10: 168-189.
22. Douglas LJ, Ballie GS (1998). Effect of growth rate on Candida albicans biofilms to antifungal agents. Antimicrob. Agents Chemother. 42: 1900-1905.
23. File TM (2003). Necrotizing soft tissue infections. Curr. Infect. Dis. Rep. 5: 407-417.
24. th ed). Lange Medical Books/McGraw Hill (Medical publishing division). pp. 313-314.
25. th ed. Blackwell Scientific Publications, London, pp. 305-331.
26. Gander S (1996). Bacterial biofilms: resistance to antimicrobial agents. J. Antimicrob. Chemother. 39: 1047-1050.
27. th ed. Blackwell Scientific Publications, London, pp. 82-96.
28. Guibal F, Moffal-Joy M, Terris B (1998). Effects of diclofenac on experimental Streptococcal necrotizing fasciitis in rabbit. Arch. Dermatol. Res. 290: 628-633.
29. Hagbery L, Erngbery I, Freter R, Lam J, Olling S, Svanborg-Eden C (1983). Ascending unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect. Immun. 40: 273-283.
30. Hawser SP, Douglas LJ (1994). Biolfilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62: 915-921.
31. th ed. Appleton and Lange, USA, pp. 290-304.
32. Helle M, Brakenhoff JPJ, de Groot ER, Aarden L (1988). Interleukin-6 is involved in interleukin-1 induced activities. Eur. J. Immunol. 18: 957-959.
33. Hoyle BD, Jass J, Costerton JW (1990). The biofilm glycocalyx as a resistance factor. J. Antimicrob. Chemother. 26: 1-5.
34. Kristiansen JE (1992). The antimicrobial activity of non-antibiotics. Acta Pathol. Microb. Scand. 100 (Suppl.): 17-19.
35. Lewis K, (2000). Programmed death in bacteria. Microbiol. Mol. Biol. Rev. 64: 503-514.
36. Lewis K, (2001). Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45: 999-1007.
37. Linder H, Enberg I, Vankooten C, de Man P, Svanborg-Eden C (1990). Effects of anti-inflammatory agents on mucosal inflammation induced by infection with gram negative bacteria. Infect. Immun. 58: 2056-2060.
38. Linder H, Enberg I, Mattsby-Baltzer I, Svanborg-Eden C (1988). Natural resistance to urinary tract infection determined by endotoxin-induced inflammation. FEMS Microbiol. Lett. 49: 219-222.
39. th ed. Prentice Hill Inc, USA.
40. nd ed Lippincott Williams and Wilkins, USA, pp. 401-420.
41. Nelle M, Boeije L, Aarden L (1988). Functional discrimination between interleukin-6 and interleukin-1. Eur. J. Immunol. 18: 1535-1540.
42. Nijsten MWN, de Groot ER, ten Duis HG, Klasen HJ, Hack CE, Aarden LA (1987). Serum levels of interleukin-6 and acute phase responses. Lancet ii: p. 921.
43. st ed. Shaneson C.I Limited, Nigeria, pp. 341-348.
44. th ed. Appleton and Lange, USA, pp. 536-560.
45. Perimutter DH, Dinnarello CA, Punsal PI, Colten HR (1986). Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J. Clin. Invest. 78: 1349-1354.
46. Potera C (1999). Forging a link between biofilms and disease. Science, 283: 1837-1839.
47. th ed. Churchill Livingstone, London, pp. 229-247.
48. th ed. Churchill Livingstone, London, pp. 198-228.
49. Rietschel ETH, Schade U, Wollenweber HW, Luderitz O, Griesman SG (1982). Bacterial endotoxins: Chemical structure, biological activity and role in septicemia. Scand. J. Infect. Dis. Suppl. 31: 8-20.
50. th ed. Appleton and Lange, USA, pp. 858- 878.
51. Sano C, Shimizu T, Sato K, Kawauchi H, Kawahara S, Tomioka H (1999). Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the non- steroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice. Antimicrob. Agents Chemother. 43: 360-364.
52. Shahin R, Engberg I, Hagberg L, Svanborg-Eden C (1987). Neutrophil recruit ment and bacterial clearance correlated with lipopolysaccharide nonresponsiveness in local gram-negative infection. Infect. Immun. 10: 3475-3480.
53. Smith RJ, Berk SL (1991). Necrotizing fasciitis and nonsteroidal antiinflammatory drugs. South Med. J. 84: 785-787.
54. Stevens DL (1995). Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin. Infect. Dis. 21: 977-980.
55. Tunney MM, Gorman SP, Patrick S (1996). Infection associated with medical devices. Rev. Med. Microbiol. 7: 195-20